Should I Buy SNBR? SNBR 2026 Analysis

Should You Buy Sleep Number Corp (SNBR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

12.370

1 Day change

4.74%

52 Week Range

18.670

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now for a short-term momentum/swing setup. The chart is in an improving uptrend (bullish MA stack and positive/expanding MACD), options positioning is call-heavy (bullish), and the news flow adds near-term visibility (Kelce equity stake + marketing). Upside is likely capped near resistance at 11.66 then 12.14; a clean break above 11.66 improves odds of a move toward ~12+. This is more of a tactical buy than a conviction long-term compounding story given the still-weak revenue trend.

Technical Analysis

Trend/price action: Despite today’s -1.34% dip to 11.19, the technical structure is bullish with SMA_5 > SMA_20 > SMA_200, suggesting an established upswing. Momentum: MACD histogram is positive (0.0609) and expanding, consistent with strengthening upside momentum; RSI_6 at 67.23 is near the upper end of neutral (not yet an extreme overbought reading). Levels: Pivot 10.893 is the key near-term line to hold; support at 10.125 then 9.651. Overhead resistance sits at R1 11.661 and R2 12.135—these are the most realistic short-term targets given current price. Probabilistic trend read: pattern analogs imply mildly positive next-day odds and modestly positive next-month bias. Intellectia Proprietary Trading Signals **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/sentiment: Open-interest put/call ratio at 0.28 is strongly call-skewed (bullish positioning). Volume put/call ratio at 0.63 is also call-leaning on the day.

Activity/interest: Total OI 15,850 with call OI 12,413 vs put OI 3,437; today’s OI vs avg +122.97% suggests elevated positioning/engagement.

Volatility: 30D IV 118.27 vs historical vol 70.56 (IV elevated), with IV percentile 80.72—options are pricing large moves, consistent with a high-beta tactical trade environment rather than a low-vol grind.

Technical Summary

Sell

Buy

Positive Catalysts

News-driven visibility: Travis Kelce becoming a minority shareholder and participating in marketing campaigns can boost brand attention and near-term sales traffic.
Analyst tone improving: Piper Sandler materially raised its price target to $12 and highlighted confidence in new CEO Linda Findley as an operational/strategic upgrade.
Technical backdrop: Bullish moving-average stack and positive MACD support follow-through attempts toward 11.66/12.14 resistance.

Neutral/Negative Catalysts

Top-line pressure: Latest reported quarter shows revenue down -19.63% YoY (demand/industry and execution headwinds still present).
Profitability still negative: Net income and EPS improved sharply YoY but remain losses (Net Income -39.79M; EPS -1.73), meaning the turnaround is not yet fully proven.
Event risk ahead: Next earnings (QDEC
on 2026-02-23 pre-market can dominate near-term price action and cap willingness to pay up ahead of the print.
Street stance still cautious overall: Both listed analyst notes maintain Neutral ratings (even with a higher PT), implying “not a clear fundamental buy” consensus.

Financial Performance

Latest quarter provided: 2025/Q3. Revenue fell to $342.879M (down -19.63% YoY), indicating ongoing demand softness. Losses narrowed materially YoY: Net income improved to -$39.79M (up 1168.81% YoY) and EPS improved to -1.73 (up 1135.71% YoY), signaling cost/actions are helping versus a weak prior-year base. Gross margin slipped to 59.9% (down -1.53% YoY), which is a mild deterioration and suggests promotions/input costs/mix pressure. Overall: financial trend is “turnaround-in-progress” (better losses) but not yet a growth story (revenue still contracting).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: Wall Street tone is neutral but improving on targets. UBS (2025-11-06) cut PT to $6 (Neutral), reflecting earlier pessimism; Piper Sandler (2026-01-16) raised PT sharply to $12 from $5 (Neutral) after positive CEO interactions, signaling rising confidence in leadership/strategy even if fundamentals still need to prove out. Pros view: management upgrade narrative + potential brand/marketing tailwinds + technical recovery. Cons view: revenue contraction and ongoing losses keep ratings at Neutral and limit upside expectations near the new $12 target. Influential/political trading: No recent congress trading data; insider and hedge fund trends are noted as Neutral with no significant recent activity.

2 Analyst Rating

Wall Street analysts forecast SNBR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNBR is 5.5 USD with a low forecast of 5 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 11.810

Low

Averages

5.5

High

Current: 11.810

Low

Averages

5.5

High

Piper Sandler

Neutral

maintain

$5 -> $12

AI Analysis

2026-01-16

Reason

Piper Sandler

Price Target

$5 -> $12

AI Analysis

2026-01-16

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Sleep Number to $12 from $5 and keeps a Neutral rating on the shares. The firm notes that while Sleep Number didn't pre-announce Q4 results, Piper had a chance to spend time with new CEO Linda Findley, and it walked away impressed and believes she represents a significant upgrade from her predecessor.

UBS

Neutral

downgrade

$7 -> $6

2025-11-06

Reason

UBS

Price Target

$7 -> $6

2025-11-06

downgrade

Neutral

Reason

UBS lowered the firm's price target on Sleep Number to $6 from $7 and keeps a Neutral rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SNBR

Unlock Now

SNBR Should I Buy

SNBR Should I Buy

Should You Buy Sleep Number Corp (SNBR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch